



VOLUME EIGHTY SIX

# ADVANCES IN INORGANIC CHEMISTRY

Edited by

**RUDI VAN ELDIK**

*Department of Chemistry and Pharmacy,  
University of Erlangen-Nuremberg, Egerlandstr. 1,  
Erlangen, Germany; Nicolaus Copernicus University in Torun,  
Gagarina 7, Torun, Poland*



ELSEVIER



**ACADEMIC PRESS**

An imprint of Elsevier

Academic Press is an imprint of Elsevier  
125 London Wall, London, EC2Y 5AS, United Kingdom  
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States

First edition 2025

Copyright © 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

For accessibility purposes, images in electronic versions of this book are accompanied by alt text descriptions provided by Elsevier. For more information, see <https://www.elsevier.com/about/accessibility>.

Books and Journals published by Elsevier comply with applicable product safety requirements. For any product safety concerns or queries, please contact our authorised representative, Elsevier B.V., at [productsafety@elsevier.com](mailto:productsafety@elsevier.com).

Publisher's note: Elsevier takes a neutral position with respect to territorial disputes or jurisdictional claims in its published content, including in maps and institutional affiliations.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: [www.elsevier.com/permissions](http://www.elsevier.com/permissions).

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

### Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-443-43082-4  
ISSN: 0898-8838

For information on all Academic Press publications  
visit our website at <https://www.elsevier.com/books-and-journals>

*Publisher:* Zoe Kruze  
*Acquisitions Editor:* Mariana L. Kuhl  
*Editorial Project Manager:* Palash Sharma  
*Production Project Manager:* Abdulla Sait  
*Cover Designer:* Arumugam Kothandan  
Typeset by MPS Limited, India



# Contents

Contributors

xiii

<b>1. Exploring Self-Assembly and the Self-Organization of Nanoscale Inorganic Polyoxometalate Clusters</b>	<b>1</b>
H.N. Miras, D.-L. Long, and L. Cronin	
1. Introduction to Polyoxometalate Chemistry	2
1.1 Background	2
1.2 Classification of the Polyoxometalate Family	2
2. From Serendipity to Directed Assembly	4
3. Synthetic Methodologies	6
3.1 Ligands and Metal Cations as Assembly Directing Motifs	6
3.2 Templated Assembly	10
3.3 Reductively Triggered Assembly	16
4. POM-Based Supramolecular Structures	18
4.1 POM Nanostructures	18
5. From Self-Assembled to Self-Organizing Cluster Systems	21
6. Conclusions	24
References	25
<b>2. Roadmap of exploring self-assembly and the self-organization of nanoscale polyoxometalate clusters</b>	<b>29</b>
De-Liang Long and Leroy Cronin	
1. Introduction	30
2. Synthetic methodologies	31
2.1 Traditional synthesis approaches	31
2.2 Advanced synthetic strategies	31
3. Building block strategy for growing gigantic POM clusters	33
3.1 Advances in Mo blues	33
3.2 New emerging of large Mo red clusters	36
3.3 Novel high nuclearity polyoxoniobates	39
3.4 Maximizing POM functionalities by mixing metals	42
3.5 Non-classical POMs	43
4. POM metal-organic hybrids	45
4.1 POM-mediated Ag clusters	45

4.2	Organic ligand directed assembly of giant POM-based cages	46
4.3	POM embedded MOF	49
5.	Self-organisation to high order materials	50
6.	Perspective	53
	Appendix. Supporting information	54
	References	54
<b>3.</b>	<b>New Insights on <math>\{\text{FeNO}\}^n</math> (<math>n=7, 8</math>) Systems as Enzyme Models and HNO Donors</b>	<b>59</b>
	Todd C. Harrop	
1.	Background	60
2.	$\{\text{FeNO}\}^7$ Complexes as Models for Nonheme Oxygenase Enzymes	61
2.1	High-spin $\{\text{FeNO}\}^7$ complexes	61
2.2	Low-spin $\{\text{FeNO}\}^7$ complexes	66
3.	$\{\text{FeNO}\}^7$ Complexes as Precursors to $\{\text{FeNO}\}^8$ Complexes	67
3.1	Low-spin $\{\text{FeNO}\}^8$ complexes	67
3.2	High-spin $\{\text{FeNO}\}^8$ complexes	71
4.	Diiron Complexes Containing $\{\text{FeNO}\}^7$ Unit(s)	73
5.	Summary and Outlook	76
	References	78
<b>4.</b>	<b>Roadmap of new insights on <math>\{\text{FeNO}\}^n</math> (<math>n = 7, 8</math>) systems as enzyme models and HNO donors</b>	<b>81</b>
	Lanjun Cheng, Jordan A. Ernst, and Todd C. Harrop	
1.	Background and guidelines	82
1.1	Guidelines	83
2.	Mononuclear $\{\text{FeNO}\}^{7/8}$ complexes	87
2.1	Four-coordinate (4C) $\{\text{FeNO}\}^{7/8}$	87
2.2	Five-coordinate (5C) $\{\text{FeNO}\}^{7/8}$	89
2.3	Six-coordinate (6C) $\{\text{FeNO}\}^{7/8}$	93
3.	Dinuclear $\{\text{FeNO}\}^7$ complexes	94
4.	Outlook	101
	References	103
<b>5.</b>	<b>Development of Trackable Anticancer Agents Based on Metal Complexes</b>	<b>105</b>
	Ewen Bodio, Pierre Le Gendre, Franck Denat, and Christine Goze	
1.	Introduction	106
2.	Coumarin-Au Theranostic Complexes	108

3. BODIPY-Based Therapeutic Metal Complexes	111
4. Porphyrin-Based Theranostics	126
5. PET SPECT Theranostics Based on Metal Complexes	132
6. Toward the Development of Smart Theranostic Phosphine-Au Agents	135
7. Toward Other Metal-Based Theranostic Systems	144
7.1 Sub-Phthalocyanine-Macrocycle Potential Theranostics	145
7.2 BODIPY-Macrocycles	146
7.3 Porphyrin Macrocycles Potential Theranostics	148
8. Conclusion and Future Directions	148
References	150
<b>6. Roadmap of development of trackable anticancer agents based on metal complexes "Strategies and Perspectives for Precision Oncology and theranostics"</b>	<b>153</b>
Ewen Bodio and Julie Pineau	
1. Introduction	154
2. Metal-based theranostic agents	156
2.1 Probe-therapeutic conjugates: A coupled approach to imaging and treatment	157
2.2 Emitting therapeutics: Therapeutic agents as intrinsic imaging probes	162
2.3 Platform-based approach	164
2.4 Probe-assisted optimization	166
2.5 Conclusion and outlook	167
3. Theranostic approaches	170
3.1 Radiotheranostics	171
3.2 Fluorescence-guided surgery (FGS)	175
4. Conclusion and outlook	177
References	179
<b>7. Luminescent Iridium(III) and Rhenium(I) Complexes as Biomolecular Probes and Imaging Reagents</b>	<b>185</b>
Kenneth Kam-Wing Lo	
1. Introduction	186
2. Bioconjugation Reagents and Biomolecular Probes	188
2.1 Bioconjugation Reagents	188
2.2 Biomolecular Probes	191
3. Cellular Probes and Imaging Reagents	199
3.1 Biotin Complexes	199
3.2 Hydrophobic Probes	201

3.3	Ion Sensors	207
3.4	Nitric Oxide Sensors	209
3.5	Poly(ethylene glycol) and Poly(ethyleneimine) Complexes	213
3.6	Sugar Conjugates	217
3.7	Bioorthogonal Probes	220
4.	Conclusion	225
	Acknowledgments	225
	References	225
<b>8.</b>	<b>Luminescent and photofunctional transition metal complexes for targeted cancer phototheranostics</b>	<b>229</b>
	Lawrence Cho-Cheung Lee and Kenneth Kam-Wing Lo	
1.	Introduction	231
2.	Bioconjugation reagents	233
2.1	Cysteine-specific complexes	233
2.2	N-Terminal cysteine-specific complexes	234
2.3	$\pi$ -Clamp-specific complexes	239
3.	Stimuli-responsive reagents	244
3.1	Thiol-responsive complexes	244
3.2	Light-responsive complexes	250
4.	Bioorthogonal reagents	253
4.1	Nitrone complexes	253
4.2	Sydnone complexes	259
4.3	Tetrazine complexes	262
5.	Conclusions and future perspectives	273
	Acknowledgments	274
	References	274
<b>9.</b>	<b>NO<sub>x</sub> Linkage Isomerization in Metal Complexes</b>	<b>277</b>
	Dennis Awasabisah and George B. Richter-Addo	
1.	Introduction	278
1.1	Modes of binding of NO <sub>x</sub> moieties in monometallic complexes	279
1.2	Methods that induce linkage isomerization	281
1.3	Techniques for detecting linkage isomers	282
1.4	Factors that affect linkage isomerization	282
2.	Linkage Isomerism in Non-Porphyrin NO <sub>x</sub> Complexes	283
2.1	Group 6 (Cr and Mo) complexes	283
2.2	Group 7 (Mn and Re) complexes	287
2.3	Group 8 (Fe, Ru, and Os) complexes	289

2.4	Group 9 (Co, Rh, and Ir) complexes	296
2.5	Group 10 (Ni, Pd, and Pt) complexes	299
3.	Linkage Isomerism in NO <sub>x</sub> -Coordinated Metalloporphyrins	305
3.1	Manganese NO <sub>x</sub> porphyrins	305
3.2	Ruthenium and iron NO <sub>x</sub> porphyrin complexes	313
3.3	Cobalt NO <sub>x</sub> porphyrins	321
3.4	Hyponitrite complexes of transition metal porphyrins	323
3.5	Heme proteins	346
4.	Conclusion	354
	Acknowledgment	354
	References	355
<b>10.</b>	<b>Roadmap of NO<sub>x</sub> linkage isomerization in metal complexes</b>	<b>363</b>
	Dennis Awasabisah and George B. Richter-Addo	
1.	Status	363
2.	Current and future challenges	367
2.1	Development and improvement of light sources for induction	367
2.2	Tuning the electronic and structural properties of the other ligands in the complex	367
2.3	Metal-NO <sub>2</sub> complexes	374
3.	Concluding remarks	377
	References	378
<b>11.</b>	<b>Opportunities and Challenges for Metal Chemistry in Molecular Imaging: From Gamma Camera Imaging to PET and Multimodality Imaging</b>	<b>381</b>
	Richard Southworth, Rafael Torres Martin de Rosales, Levente K. Meszaros, Michelle T. Ma, Gregory E.D. Mullen, Gilbert Fruhwirth, Jennifer D. Young, Cinzia Imberti, Julia Bagunya-Torres, Erica Andreozzi, and Philip J. Blower	
1.	Introduction	382
2.	Technetium-99m: Small Complexes	384
2.1	From Serendipity to Design	384
2.2	Tc(I)tricarbonyl	385
2.3	Tc(V) Complexes	386
2.4	Bioconjugates: A New Challenge	388
2.5	Bioconjugation with Hynic	388
2.6	Bioconjugation with Other Bifunctional Chelators	390
2.7	Bioconjugation with the "Tricarbonyl Core" Tc(CO) <sub>3</sub> <sup>+</sup>	391

2.8	Bioconjugation by Direct Labeling Via Cysteine	393
2.9	Rhenium Analogs	393
2.10	Summary: Challenges in Tc-99m Chemistry	394
3.	The Transition Toward PET	394
3.1	The Need for Metallic Positron Emitters	394
3.2	Gallium-68: "The New Technetium-99m"	395
3.3	Zirconium-89: "The New Indium-111"—ImmunoPET and Cell Tracking	397
4.	Copper: Exploiting Redox Chemistry	399
4.1	Copper Isotopes and Bioconjugates	399
4.2	Bioreductive Trapping—Imaging Blood Flow and Hypoxia	401
4.3	Cell Tracking with Copper	408
4.4	Copper Trafficking Pathways in Health and Disease	409
5.	Inorganic Elements as Binding Sites for $^{18}\text{F}$ -Fluoride	411
6.	Multimodality Imaging and Nanoparticulate Contrast Agents	412
7.	Summary and Conclusion	416
	Acknowledgments	416
	References	416
<b>12.</b>	<b>Roadmap of opportunities and challenges for metal chemistry in molecular imaging: From gamma camera imaging to PET and multimodality imaging</b>	<b>423</b>
	Cinzia Imberti and Philip J. Blower	
1.	Introduction	424
2.	Technetium-99m	425
2.1	Evolution of technetium-99m radiopharmaceuticals	425
2.2	Bioconjugates of technetium: Design specifications	425
2.3	Technetium bioconjugates: A lost decade	426
2.4	Bioconjugates of new technetium cores: The $\text{Tc}(\text{VO}_2)^+$ bis (diphosphine) core	426
2.5	Other new technetium cores	427
2.6	The roadmap of clinical translation of technetium bioconjugates	428
2.7	Summary: Challenges in technetium-99m chemistry	430
3.	The transition towards PET	430
3.1	The need for metallic positron emitters	430
3.2	Scandium-44	431
3.3	Titanium-45	434
3.4	Manganese-52	434
3.5	Copper radionuclides	434

---

3.6 Gallium-68: "the new technetium-99m."	435
3.7 Rubidium-82	437
3.8 Zirconium-89: Prolonged PET imaging	437
3.9 Technetium-94m	438
3.10 Terbium-152	439
4. Declining radiometals	439
5. Metals as binding sites for $^{18}\text{F}$ -fluoride	439
6. Nanoparticulates and nanomedicines	440
7. Imaging in metallomics	441
7.1 Endogenous metals	441
7.2 Metallodrugs	443
7.3 Metal contaminants	444
7.4 Imaging metallomics: Future prospects	444
8. Total body PET (TBP)	444
9. Summary	445
Acknowledgements	446
References	447
<i>Index</i>	453